Human Leukocyte Antigen Fairness in Novel T-Cell Receptor Therapies.

HLA restrictions limit the applicability of T-cell receptor therapies across genetically diverse human populations, creating fairness challenges that stakeholders must address.

• Why it matters: Genetic diversity in human populations means many patients may not match the HLA requirements of TCR therapies, risking unequal access and outcomes.
• What they did: This Viewpoint discusses the role of HLA restrictions in limiting TCR therapy applicability and outlines how stakeholders can respond to disparities.
• The result: It frames fairness considerations for novel TCR therapies, highlighting the need for strategies that reduce HLA-linked inequities in genetically diverse populations.

AI summary of the abstract · may contain errors · not medical advice · read the paper.